NCT02318693View on ClinicalTrials.gov

Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)

PHASE4CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

February 4, 2015

Primary Completion Date

December 15, 2015

Study Completion Date

December 15, 2015

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Sitagliptin

Sitagliptin 50 mg orally once a day before breakfast for 14 days

DRUG

Glibenclamide

Glibenclamide 1.25 mg orally twice a day (2.5 mg/day) before breakfast and dinner for 14 days

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02318693 - Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355) | Biotech Hunter | Biotech Hunter